Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. The dialysis machine may include at least one processor and a memory coupled to the at least one processor, the memory comprising instructions that, when executed by the processor, may cause the at least one processor to access dialysis information for a dialysis process performed by a dialysis machine, the dialysis information indicating a target substance to be displaced from a binding compound by a displacer, and determine an infusion profile for infusing the displacer into a patient during a displacer infusion process of the dialysis process, the infusion profile determined based on the dialysis information and an infusion constraint. Other embodiments are described.

A dialyzer includes a dialysis unit including a blood channel and a dialysate channel; a dialysate supply channel configured to supply a dialysate to the dialysate channel; a dialysate discharge channel configured to discharge the dialysate from the dialysate channel; a blood supply channel configured to supply blood to the blood channel, and a blood discharge channel configured to discharge the blood from the blood channel. The dialysate contains nitric oxide and/or nitrite ions, and the concentration of the nitric oxide is 0.5 to 10 μM or the concentration of the nitrite ions is 40 to 120 μM.

A system for producing fluid for peritoneal dialysis (PD) is disclosed. The system includes a fluid path including two or more PD concentrate connectors that are each connected to a source of PD concentrate fluid, and an inlet connector connected to a fluid line arranged for transportation of effluent fluid from a patient. The system also includes a forward osmosis (FO)-unit including a draw side and a feed side separated by a FO-membrane. The FO-unit is fluidly connected to the fluid path and receives one or more PD concentrate fluids at the draw side and the effluent at the feed side. Water is transported from the effluent to the one or more PD concentrate fluids through the FO-membrane via an osmotic pressure gradient between the draw side and the feed side, thereby diluting the one or more PD concentrate fluids into a diluted PD concentrate fluid.

A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 μm.

A peritoneal dialysis system and method includes a control unit configured to enable a pressurization device to pressurize a pressure cavity to a pressure; cause a fluid valve to be opened when the pressure reaches a desired pressure to allow fluid communication with a flexible container located within the pressure cavity; cause a pressure within the pressure cavity to be measured after the fluid valve is opened; and determine that the flexible container is full of fluid or empty of fluid if the pressure within the pressure cavity after the fluid valve is opened becomes or remains at least substantially constant.

The present invention relates to the field of medical devices, more particularly the field of devices for extracting circulating molecules from the blood of a mammal, and their therapeutic uses, in particular in treating sepsis, cytokine release syndrome and/or any other form of systemic inflammatory response or cytokine shock, caused by bacterial, parasitic, fungal or viral infections, in particular caused by a viral infection, for example coronaviruses with human respiratory tract tropism.

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.

The present disclosure provides compositions and methods for treating cancer with nutritionally modified diets and/or dialysis treatment, such as through amino acid depletion of one or more nonessential amino acids. In some aspects, the present disclosure provides compositions and methods for treating obesity with such modified diets and/or dialysis treatment. Furthermore, in some aspects, the present disclosure provides compositions and methods for treating renal disease with such modified diets and/or dialysis treatment.

The invention provides a source of sodium thiosulfate via the dialysate used to cleanse the bool of toxic and metabolic waste in the patients undergoing hemodialysis, peritoneal dialysis, or gastro-intestinal dialysis for treatment of end-stage or near end-stage chronic renal disease. In the method of the invention, dialysis solution components contain therapeutic amounts of sodium thiosulfate, which when fully reconstituted for use as a single solution, deliver 20-130 mg/dl of dialysate.

The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.